In this episode, Rachel Wolfson and Charlie Lee –- creator of Litecoin, one of the earliest and most influential cryptocurrencies in the world –- sit down to discuss the development of Litecoin. From launching Litecoin …
Join Valdrin Tahiri from CCN in conversation with Litecoin creator Charlie Lee to discuss the landscape surrounding Litecoin digital asset treasuries.
…
Litecoin creator Charlie Lee joins “CoinDesk Spotlight” to break down the roles of bitcoin and Litecoin in the cryptocurrency and broader financial industry. Plus, the journey from being an early gold bug to buying bitcoin …
Charlie Lee, Creator of Litecoin, joins Remy Blaire to discuss Litecoin, a digital currency designed to be a faster and cheaper alternative to Bitcoin, while also incorporating optional privacy features.
…
MEI Pharma (now rebranded as Lite Strategy) has become the first U.S.-listed company to adopt Litecoin as a primary reserve asset, committing $100 million to the cryptocurrency as part of its new treasury strategy.
…
Lite Strategy Rebrand Aligns with Company’s LTC Digital Asset Treasury Strategy Advised by GSR Ventures SAN DIEGO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name …
SAN DIEGO–(BUSINESS WIRE)–Aug. 5, 2025– MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury …
SAN DIEGO–(BUSINESS WIRE)–Jul. 18, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale …
SAN DIEGO–(BUSINESS WIRE)–Jul. 22, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has closed its previously announced private placement for the purchase and sale of 29,239,767 shares of common stock (or …
Evaluation of Strategic Alternatives is Ongoing SAN DIEGO–(BUSINESS WIRE)–May 13, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing …
Evaluation of Strategic Alternatives is Ongoing SAN DIEGO–(BUSINESS WIRE)–Feb. 12, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its …
